slides · global inventory
Title
Component collection for the active corpus filters, with each row opening the slide detail view.
Matching slides 303,780
Current window 226,711-226,740
Pages 10,126
Rows per page 30
Component
226,711-226,740 of 303,780
31
Kymera | Investor Presentation Deck | 41 slidesKymera | Investor Presentation Deck | 41 slides · Kymera
Pitch deck Investor relations 1 hit
33
Includes three dose-response curves and a comparative table of clinical stage and potency metrics.Kymera | Investor Presentation Deck | 41 slides · Kymera
Pitch deck Investor relations 1 hit
34
Comparison of KT-253 vs DS-3032 (SMI) across protein levels and tumor volume over time.Kymera | Investor Presentation Deck | 41 slides · Kymera
Pitch deck Investor relations 1 hit
35
Includes a visual representation of the dose escalation study design and a detailed table of patient baseline characteristics.Kymera | Investor Presentation Deck | 41 slides · Kymera
Pitch deck Investor relations 1 hit
36
The slide combines a biological mechanism diagram with clinical trial data (table and line chart) to validate the drug's mechanism of action.Kymera | Investor Presentation Deck | 41 slides · Kymera
Pitch deck Investor relations 1 hit
37
Swimmer plot showing days on study for three patients, with corresponding CT scan imagery for one patient.Kymera | Investor Presentation Deck | 41 slides · Kymera
Pitch deck Investor relations 1 hit
38
Clinical trial safety reporting slide.Kymera | Investor Presentation Deck | 41 slides · Kymera
Pitch deck Investor relations 1 hit
39
The slide uses a split-layout to contrast technical mechanism/data (left) with strategic market opportunity (right).Kymera | Investor Presentation Deck | 41 slides · Kymera
Pitch deck Investor relations 1 hit
40
Kymera | Investor Presentation Deck | 41 slidesKymera | Investor Presentation Deck | 41 slides · Kymera
Pitch deck Investor relations Beat · Roadmap1 hit
02
Larimar Therapeutics | Investor Presentation Deck | 44 slidesLarimar Therapeutics | Investor Presentation Deck | 44 slides · Larimar Therapeutics
Pitch deck Investor relations 1 hit
03
The slide uses a list-based layout to present key company milestones and financial health.Larimar Therapeutics | Investor Presentation Deck | 44 slides · Larimar Therapeutics
Pitch deck Investor relations Beat · Executive Summary1 hit
04
The slide uses a two-column layout to contrast the current Phase 2 trial status with the upcoming OLE trial status.Larimar Therapeutics | Investor Presentation Deck | 44 slides · Larimar Therapeutics
Pitch deck Investor relations Beat · Traction1 hit
05
The slide uses a timeline framework to demonstrate long-term IP protection.Larimar Therapeutics | Investor Presentation Deck | 44 slides · Larimar Therapeutics
Pitch deck Investor relations Beat · Traction1 hit
06
The slide uses a medical context to establish the severity of the condition and the unmet medical need.Larimar Therapeutics | Investor Presentation Deck | 44 slides · Larimar Therapeutics
Pitch deck Investor relations Beat · ProblemLoop · Cost Of Inaction1 hit
09
Details the dosing schedule (13 days) and specific sampling days for buccal cells, skin, and platelets across three dose levels.Larimar Therapeutics | Investor Presentation Deck | 44 slides · Larimar Therapeutics
Pitch deck Investor relations Beat · TractionLoop · Golden Circle1 hit
10
The slide displays two dot plots with error bars representing median and 25th/75th percentiles for FXN concentration changes from baseline.Larimar Therapeutics | Investor Presentation Deck | 44 slides · Larimar Therapeutics
Pitch deck Investor relations Beat · Traction1 hit
11
The slide outlines the methodology for a clinical trial, specifically focusing on the 28-day treatment schedule and cohort details.Larimar Therapeutics | Investor Presentation Deck | 44 slides · Larimar Therapeutics
Pitch deck Investor relations Beat · Traction1 hit
12
Data represents median and 25th/75th percentiles. Baseline values provided in footnotes.Larimar Therapeutics | Investor Presentation Deck | 44 slides · Larimar Therapeutics
Pitch deck Investor relations Beat · Traction1 hit
13
The slide establishes a baseline for FXN levels in healthy individuals to contextualize the deficiency seen in Friedreich's Ataxia (FA) patients.Larimar Therapeutics | Investor Presentation Deck | 44 slides · Larimar Therapeutics
Pitch deck Investor relations Beat · Traction1 hit
14
The slide highlights high completion rates and manageable adverse events, specifically noting injection site reactions (ISRs) as the most common side effect.Larimar Therapeutics | Investor Presentation Deck | 44 slides · Larimar Therapeutics
Pitch deck Investor relations Beat · Traction1 hit
15
FACOMS: Friedreich's Ataxia Clinical Outcome Measures StudyLarimar Therapeutics | Investor Presentation Deck | 44 slides · Larimar Therapeutics
Pitch deck Investor relations Beat · TractionLoop · Quick Win Big Bet1 hit
17
The slide highlights the unique 'Protein replacement' approach of Nomlabofusp compared to other modalities like Mitochondrial Oxidative Stress Modifiers, Gene Expression Regulators, Pathway Modifiers, and Gene Therapy.Larimar Therapeutics | Investor Presentation Deck | 44 slides · Larimar Therapeutics
Pitch deck Investor relations Beat · TractionLoop · Quick Win Big Bet1 hit
18
Larimar Therapeutics | Investor Presentation Deck | 44 slidesLarimar Therapeutics | Investor Presentation Deck | 44 slides · Larimar Therapeutics
Pitch deck Investor relations Beat · TractionLoop · Quick Win Big Bet1 hit
19
The slide uses a list-based layout to present key company milestones and status.Larimar Therapeutics | Investor Presentation Deck | 44 slides · Larimar Therapeutics
Pitch deck Investor relations Beat · Traction1 hit
21
Larimar Therapeutics | Investor Presentation Deck | 44 slidesLarimar Therapeutics | Investor Presentation Deck | 44 slides · Larimar Therapeutics
Pitch deck Investor relations Beat · Traction1 hit
22
Larimar Therapeutics | Investor Presentation Deck | 44 slidesLarimar Therapeutics | Investor Presentation Deck | 44 slides · Larimar Therapeutics
Pitch deck Investor relations Beat · Traction1 hit
23
The slide serves as a credibility-building asset by showcasing a partnership with a key non-profit organization in the rare disease space.Larimar Therapeutics | Investor Presentation Deck | 44 slides · Larimar Therapeutics
Pitch deck Investor relations Beat · Traction1 hit
24
Larimar Therapeutics | Investor Presentation Deck | 44 slidesLarimar Therapeutics | Investor Presentation Deck | 44 slides · Larimar Therapeutics
Pitch deck Investor relations Beat · Traction1 hit
25
The slide outlines the clinical trial methodology for a drug candidate in Friedreich's Ataxia (FA) patients.Larimar Therapeutics | Investor Presentation Deck | 44 slides · Larimar Therapeutics
Pitch deck Investor relations Beat · Traction1 hit
27
The charts display median values with 25th and 75th percentile error bars.Larimar Therapeutics | Investor Presentation Deck | 44 slides · Larimar Therapeutics
Pitch deck Investor relations Beat · Traction1 hit